AnaptysBio Inc. (ANAB)
AnaptysBio Statistics
Share Statistics
AnaptysBio has 30.67M shares outstanding. The number of shares has increased by 12.26% in one year.
| Shares Outstanding | 30.67M |
| Shares Change (YoY) | 12.26% |
| Shares Change (QoQ) | 0.78% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 28.29M |
| Failed to Deliver (FTD) Shares | 8.13K |
| FTD / Avg. Volume | 0.79% |
Short Selling Information
The latest short interest is 6.6M, so 21.68% of the outstanding shares have been sold short.
| Short Interest | 6.6M |
| Short % of Shares Out | 21.68% |
| Short % of Float | 25.47% |
| Short Ratio (days to cover) | 10.19 |
Valuation Ratios
The PE ratio is -2.59 and the forward PE ratio is -3.06. AnaptysBio's PEG ratio is 0.16.
| PE Ratio | -2.59 |
| Forward PE | -3.06 |
| PS Ratio | 4.12 |
| Forward PS | 4.3 |
| PB Ratio | 5.3 |
| P/FCF Ratio | -2.77 |
| PEG Ratio | 0.16 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for AnaptysBio.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.51, with a Debt / Equity ratio of 0.23.
| Current Ratio | 9.51 |
| Quick Ratio | 9.51 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | -0.17 |
| Debt / FCF | -0.12 |
| Interest Coverage | -2.29 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $671.18K |
| Profits Per Employee | $-1.07M |
| Employee Count | 136 |
| Asset Turnover | 0.19 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 3K |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -8.45% in the last 52 weeks. The beta is 0.03, so AnaptysBio's price volatility has been higher than the market average.
| Beta | 0.03 |
| 52-Week Price Change | -8.45% |
| 50-Day Moving Average | 17.18 |
| 200-Day Moving Average | 25.07 |
| Relative Strength Index (RSI) | 58.53 |
| Average Volume (20 Days) | 1.03M |
Income Statement
In the last 12 months, AnaptysBio had revenue of 91.28M and earned -145.23M in profits. Earnings per share was -5.12.
| Revenue | 91.28M |
| Gross Profit | 91.28M |
| Operating Income | -114.95M |
| Net Income | -145.23M |
| EBITDA | -92.74M |
| EBIT | -95.14M |
| Earnings Per Share (EPS) | -5.12 |
Balance Sheet
The company has 123.08M in cash and 16.04M in debt, giving a net cash position of 107.04M.
| Cash & Cash Equivalents | 123.08M |
| Total Debt | 16.04M |
| Net Cash | 107.04M |
| Retained Earnings | -759.33M |
| Total Assets | 483.83M |
| Working Capital | 386.45M |
Cash Flow
In the last 12 months, operating cash flow was -135.34M and capital expenditures -358K, giving a free cash flow of -135.69M.
| Operating Cash Flow | -135.34M |
| Capital Expenditures | -358K |
| Free Cash Flow | -135.69M |
| FCF Per Share | -4.78 |
Margins
Gross margin is 100%, with operating and profit margins of -125.93% and -159.1%.
| Gross Margin | 100% |
| Operating Margin | -125.93% |
| Pretax Margin | -159.1% |
| Profit Margin | -159.1% |
| EBITDA Margin | -101.6% |
| EBIT Margin | -125.93% |
| FCF Margin | -148.66% |
Dividends & Yields
ANAB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ANAB is $38, which is 100.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $38 |
| Price Target Difference | 100.3% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Scores
| Altman Z-Score | -0.88 |
| Piotroski F-Score | 3 |